Market Place
Sourcing Support
Taysha Gene Therapies To Present AAV9 Biodistribution Data
22 Oct 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
04 Oct 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Presentation On TSHA-102
26 Sep 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Rule
06 Sep 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies To Report Q2 2024 Results On August 12
05 Aug 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule
02 Aug 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Pricing Of Public Offering
26 Jun 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Public Offering of Common Stock
25 Jun 2024 //
GLOBENEWSWIRE
Taysha Reports Positive TSHA-102 Data In Rett Syndrome Trials
18 Jun 2024 //
PRESS RELEASE
Taysha To Present REVEAL Rett Syndrome Data At IRSF Meeting
12 Jun 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Reports Inducement Grant
07 Jun 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Q1 2024 Results, Call & Webcast on May 14
06 May 2024 //
GLOBENEWSWIRE
Taysha Announces Nasdaq Listing Rule Inducement Grant
03 May 2024 //
GLOBENEWSWIRE
Taysha: FDA RMAT For TSHA-102 In Rett Syndrome
02 May 2024 //
GLOBENEWSWIRE
Taysha Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
Taysha Gene Reports Full Year 2023 Financial Results
19 Mar 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies to Release Full-Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
29 Feb 2024 //
GLOBENEWSWIRE
After patient outcry, Taysha starts to offload drug programs
16 Feb 2024 //
ENDPTS
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
15 Feb 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome
22 Jan 2024 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102
10 Jan 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
GLOBENEWSWIRE
Taysha Gene Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial
29 Nov 2023 //
GLOBENEWSWIRE
Patient foundation accuses rare disease company Taysha of violating agreement
16 Nov 2023 //
ENDPTS
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies to Release Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Taysha Gene Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome
24 Oct 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102
10 Oct 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102
26 Sep 2023 //
GLOBENEWSWIRE
Taysha ends work on gene therapy after Astellas walks away
19 Sep 2023 //
FIERCE BIOTECH
Taysha Gene Therapies Provides Update on TSHA-120 Program in GAN
19 Sep 2023 //
GLOBENEWSWIRE
Taysha Gene Announces Fast Track Designation Granted by FDA for TSHA-102
24 Aug 2023 //
GLOBENEWSWIRE
GordonMD® Invests in Private Placement for Taysha Gene Therapies
21 Aug 2023 //
BUSINESSWIRE
Taysha Gene Reports Data from Rett Syndrome Patient Dosed in Phase 1/2 Trial
14 Aug 2023 //
GLOBENEWSWIRE
Taysha raises $150M PIPE, shares single patient data on gene therapy
14 Aug 2023 //
ENDPTS
Nasdaq threatens to delist Taysha Gene Therapies
08 Aug 2023 //
ENDPTS
Taysha Gene Provides Clinical Updates for Investigational Programs TSHA-120
28 Jun 2023 //
GLOBENEWSWIRE
Taysha Gene to Host Virtual R&D Day on Lead Clinical Investig Programs TSHA-120
15 Jun 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102
05 Jun 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome
19 May 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies to Release 1Q 2023 FYR & Host Conference Call
04 May 2023 //
GLOBENEWSWIRE
Taysha Gene Announces Presentation on New Preclinical Data for TSHA-102
27 Apr 2023 //
GLOBENEWSWIRE
Taysha Gene Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Taysha Gene to Release Fourth Quarter and Full-Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Taysha Gene Provides Update on TSHA-120 Program in Giant Axonal Neuropathy
31 Jan 2023 //
GLOBENEWSWIRE
Taysha Gene Therapies Makes Executive Leadership Changes
19 Dec 2022 //
CONTRACTPHARMA
Taysha CEO steps down after patent fights with patient families, job cuts
19 Dec 2022 //
ENDPTS
Taysha Gene Therapies Makes Executive Leadership Changes
19 Dec 2022 //
CONTRACTPHARMA
Taysha CEO steps down after patent fights with patient families, job cuts
19 Dec 2022 //
ENDPTS
Taysha Gene Therapies Announces Executive Leadership Changes
16 Dec 2022 //
GLOBENEWSWIRE
Taysha to Participate in JMP Securities Hematology and Oncology Summit
29 Nov 2022 //
GLOBENEWSWIRE
Taysha Gene Therapies Reports3Q 2022 Financial Results
08 Nov 2022 //
BIOSPACE
